Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Dr. Reddy's Laboratories Limited

SG&A Expenses: Dr. Reddy's vs. Insmed (2014-2023)

__timestampDr. Reddy's Laboratories LimitedInsmed Incorporated
Wednesday, January 1, 20143878300000031073000
Thursday, January 1, 20154258500000043216000
Friday, January 1, 20164570200000050679000
Sunday, January 1, 20174637200000079171000
Monday, January 1, 201846910000000168218000
Tuesday, January 1, 201948890000000210796000
Wednesday, January 1, 202050129000000203613000
Friday, January 1, 202154559000000234273000
Saturday, January 1, 202262081000000265784000
Sunday, January 1, 2023105931000000344501000
Monday, January 1, 202477201000000
Loading chart...

Cracking the code

A Tale of Two Companies: SG&A Expenses in Focus

In the ever-evolving pharmaceutical industry, operational efficiency is key to success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and Dr. Reddy's Laboratories Limited from 2014 to 2023. Over this period, Dr. Reddy's Laboratories consistently outpaced Insmed in SG&A spending, with a staggering 1,059% increase by 2023 compared to 2014. In contrast, Insmed's SG&A expenses grew by approximately 1,008% over the same period. Notably, Dr. Reddy's Laboratories experienced a significant spike in 2023, reaching a peak of 105.9 billion, while Insmed's data for 2024 remains unavailable. This trend highlights the contrasting strategies of these two companies, with Dr. Reddy's focusing on expansive growth and Insmed maintaining a more conservative approach. As the industry continues to evolve, these insights provide a glimpse into the financial strategies shaping the future of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025